US Edition
Metastatic BRAFV600-Mutated Melanoma: First Immunotherapy and Then Kinase Inhibitors – Deutsches Ärzteblatt
Summary by Deutsches Ärzteblatt
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Chicago – In the DREAMseq study, researchers are testing the efficacy and safety of a specific treatment sequence in patients with BRAFV600-mutated metastatic melanoma. The sequence of nivolumab/ipilimumab (N/I) followed by dabrafenib/trametinib (D/T) proved superior to the reverse sequence. The five-year update, which...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
